KCNQ2 and Cognitive impairment: Since changes in gamma oscillation power may provide a disease biomarker to investigate novel therapies against cognitive impairment in diseases (Honda et al., 2020; Meier et al., 2020), the present data suggest that KCa2, KCNQ2/3, and T-type calcium channel modulators might be promising targets in these states.